

Vassilis L. Souliotis

Research Director
Institute of Chemical Biology (ICB)
National Hellenic Research Foundation

Phone: +30-210-7273734

Fax: +30-210-7273677

E-mail: vl@eie.gr

RESEARCH POSITIONS

- 2017 - present** **Research Director**
Institute of Chemical Biology, National Hellenic Research Foundation
- 2017 - present** **Research Fellow**
Department of Propaedeutic Internal Medicine and Joint
Rheumatology Program, Medical School, National and Kapodistrian
University of Athens

PREVIOUS POSITIONS

- 2001-2017** **Senior Researcher**
Institute of Biological Research and Biotechnology, National Hellenic
Research Foundation
- 1987 – 2001** **Postdoctoral Fellow**
Institute of Biological Research and Biotechnology, National Hellenic
Research Foundation

RESEARCH PROFILE

Dr. Vassilis L. Souliotis has been a group leader at the Institute of Chemical Biology, National Hellenic Research Foundation since 2001. His research interests focus in the field of cellular DNA damage response (DDR) network, with a longstanding interest in the area of DNA damage formation and repair following exposure to genotoxic agents. **Dr. Souliotis' group** is focusing on genotoxic drugs (melphalan, platinum-based drugs) in order to assess the prospect of designing cancer chemotherapy protocols of improved efficacy through the optimization of the induction of cytotoxic DNA damage and to examine interindividual

variation in DNA repair as a marker for predicting differences in therapeutic response and long-term outcome. Over the past few years, he is also working on the pathogenetic mechanisms of autoimmune diseases, by studying the interplay between the DDR network and the immune system.

RESEARCH RECORDS

- Publications in international peer review journals: **58**
- Citations: **1454**
- Publications in proceedings of Greek and international conferences: **115**
- Sum Journal Impact Factors: **~298**
- h-Index: **21**
- i10-index: **42**

PUBLICATIONS IN REFEREED JOURNALS

1. **Souliotis VL**, Vlachogiannis NI, Pappa M, Argyriou A, Ntouros PA, Sfikakis PP. DNA Damage Response and Oxidative Stress in Systemic Autoimmunity. *Int J Mol Sci*. 2019 Dec 20;21(1). pii: E55. doi: 10.3390/ijms21010055.
2. **Souliotis VL**, Vlachogiannis NI, Pappa M, Argyriou A, Sfikakis PP. DNA damage accumulation, defective chromatin organization and deficient DNA repair capacity in patients with rheumatoid arthritis. *Clin Immunol*. 2019 Jun;203:28-36. doi: 10.1016/j.clim.2019.03.009.
3. Galanos P, Pappas G, Polyzos A, Kotsinas A, Svolaki I, Giakoumakis NN, Glytsou C, Pateras IS, Swain U, **Souliotis VL**, Georgakilas AG, Geacintov N, Scorrano L, Lukas C, Lukas J, Livneh Z, Lygerou Z, Chowdhury D, Sørensen CS, Bartek J, Gorgoulis VG. Mutational signatures reveal the role of RAD52 in p53-independent p21-driven genomic instability. *Genome Biol*. 2018 Mar 16;19(1):37. doi: 10.1186/s13059-018-1401-9.
4. Fragkioudaki S, Nezos A, **Souliotis VL**, Chatziandreou I, Saetta AA, Drakoulis N, Tzioufas AG, Voulgarelis M, Sfikakis PP, Koutsilieris M, Crow MK, Moutsopoulos HM, Mavragani CP. MTHFR gene variants and non-MALT lymphoma development in primary Sjogren's syndrome. *Sci Rep*. 2017 Aug 4;7(1):7354. doi: 10.1038/s41598-017-07347-w.
5. **Souliotis VL**, Vougas K, Gorgoulis VG, Sfikakis PP. Defective DNA repair and chromatin organization in patients with quiescent systemic lupus erythematosus. *Arthritis Res Ther*. 2016 Aug 4;18(1):182. doi: 10.1186/s13075-016-1081-3.
6. Gkatzamanidou M, Terpos E, Bamia C, Munshi NC, Dimopoulos MA, **Souliotis VL**. DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7. *Blood*. 2016 Sep 1;128(9):1214-25. doi: 10.1182/blood-2016-01-691618.
7. Westberg EA, Singh R, Hedebrant U, Koukouves G, **Souliotis VL**, Farmer PB, Segerbäck D, Kyrtopoulos S, Törnqvist MÅ. Adduct levels from benzo[a]pyrenediol epoxide: Relative

- formation to histidine in serum albumin and to deoxyguanosine in DNA in vitro and in vivo in mice measured by LC/MS-MS methods. *Toxicol Lett.* 2015;232:28-36. doi: 10.1016/j.toxlet.2014.09.019.
8. **Souliotis VL**, Sfrikakis PP. Increased DNA double-strand breaks and enhanced apoptosis in patients with lupus nephritis. *Lupus.* 2015 Jul;24(8):804-15. doi: 10.1177/0961203314565413.
 9. Stefanou DT, Bamias A, Episkopou H, Kyrtopoulos SA, Likka M, Kalampokas T, Photiou S, Gavalas N, Sfrikakis PP, Dimopoulos MA, **Souliotis VL**. Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer. *PLoS One.* 2015 Feb 6;10(2):e0117654. doi: 10.1371/journal.pone.0117654.
 10. Gkatzamanidou M, Sfrikakis PP, Kyrtopoulos SA, Bamia C, Dimopoulos MA, **Souliotis VL**. Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma. *Br J Cancer.* 2014 Sep 23;111(7):1293-304. doi: 10.1038/bjc.2014.410.
 11. Gkatzamanidou M, Terpos E, Bamia C, Kyrtopoulos SA, Sfrikakis PP, Dimopoulos MA, **Souliotis VL**. Progressive changes in chromatin structure and DNA damage response signals in bone marrow and peripheral blood during myelomagenesis. *Leukemia.* 2014 May;28(5):1113-21. doi: 10.1038/leu.2013.284.
 12. Stellas D, **Souliotis VL**, Bekyrou M, Smirlis D, Kirsch-Volders M, Degrossi F, Cundari E, Kyrtopoulos SA. Benzo[a]pyrene-induced cell cycle arrest in HepG2 cells is associated with delayed induction of mitotic instability. *Mutat Res.* 2014 Nov;769:59-68. doi: 10.1016/j.mrfmmm.2014.07.004.
 13. Gkatzamanidou M, Christoulas D, **Souliotis VL**, Papatheodorou A, Dimopoulos MA, Terpos E. Angiogenic cytokines profile in smoldering multiple myeloma: no difference compared to MGUS but altered compared to symptomatic myeloma. *Med Sci Monit.* 2013;20;19:1188-94. doi: 10.12659/MSM.889752.
 14. Stefanou DT, Episkopou H, Kyrtopoulos SA, Bamias A, Gkatzamanidou M, Bamia C, Liakou C, Bekyrou M, Sfrikakis PP, Dimopoulos MA, **Souliotis VL**. Development and validation of a PCR-based assay for the selection of patients more likely to benefit from therapeutic treatment with alkylating drugs. *Br J Clin Pharmacol.* 2012 Nov;74(5):842-53. doi: 10.1111/j.1365-2125.2012.04274.x.
 15. Episkopou H, Kyrtopoulos SA, Sfrikakis PP, Dimopoulos MA, **Souliotis VL**. The repair of melphalan-induced DNA adducts in the transcribed strand of active genes is subject to a strong polarity effect. *Mutat Res.* 2011 Sep 1;714(1-2):78-87. doi: 10.1016/j.mrfmmm.2011.06.012.
 16. Episkopou H, Kyrtopoulos SA, Sfrikakis PP, Fousteri M, Dimopoulos MA, Mullenders LH, **Souliotis VL**. Association between transcriptional activity, local chromatin structure, and the efficiencies of both subpathways of nucleotide excision repair of melphalan adducts. *Cancer Res.* 2009 May 15;69(10):4424-33. doi: 10.1158/0008-5472.CAN-08-3489.
 17. Dimopoulos MA, **Souliotis VL**, Anagnostopoulos A, Bamia C, Pouli A, Baltadakis I, Terpos E, Kyrtopoulos SA, Sfrikakis PP. Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma. *Haematologica.* 2007;92:1505-12. doi: 10.3324/haematol.11435.

18. Sfrikakis PP, **Souliotis VL**, Fragiadaki KG, Moutsopoulos HM, et al. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. *Clin Immunol.* 2007;123:66-73. doi: 10.1016/j.clim.2006.12.006.
19. **Souliotis VL**, Dimopoulos MA, Episkopou HG, Kyrtopoulos SA, Sfrikakis PP. Preferential in vivo DNA repair of melphalan-induced damage in human genes is greatly affected by the local chromatin structure. *DNA Repair (Amst).* 2006;5:972-85. doi: 10.1016/j.dnarep.2006.05.006.
20. Singh R, Gaskell M, Le Pla RC, Kaur B, Azim-Araghi A, Roach J, Koukouves G, **Souliotis VL**, Kyrtopoulos SA, Farmer PB. Detection and quantitation of benzo[a]pyrene-derived DNA adducts in mouse liver by liquid chromatography-tandem mass spectrometry: comparison with ³²P-postlabeling. *Chem Res Toxicol.* 2006;19:868-78. doi: 10.1021/tx060011r.
21. Dimopoulos MA, **Souliotis VL**, Anagnostopoulos A, Papadimitriou C, Sfrikakis PP. Extent of damage and repair in the p53 tumor-suppressor gene after treatment of myeloma patients with high-dose melphalan and autologous blood stem-cell transplantation is individualized and may predict clinical outcome. *J Clin Oncol.* 2005;23:4381-9. doi: 10.1200/JCO.2005.07.385.
22. **Souliotis VL**, Sfrikakis PP, Anderson LM, Kyrtopoulos SA. Intra- and intercellular variations in the repair efficiency of O6-methylguanine, and their contribution to kinetic complexity. *Mutat Res.* 2004;568:155-70. doi: 10.1016/j.mrfmmm.2004.07.009.
23. **Souliotis VL**, Dimopoulos MA, Sfrikakis PP. Gene-specific formation and repair of DNA monoadducts and interstrand cross-links after therapeutic exposure to nitrogen mustards. *Clin Cancer Res.* 2003;9:4465-74. PMID: 14555520.
24. Katsiari CG, Liossis SN, **Souliotis VL**, Dimopoulos AM, Manoussakis MN, Sfrikakis PP. Aberrant expression of the costimulatory molecule CD40 ligand on monocytes from patients with systemic lupus erythematosus. *Clin Immunol.* 2002;103:54-62. doi: 10.1006/clim.2001.5172.
25. **Souliotis VL**, Henneman JR, Reed CD, Chhabra SK, Diwan BA, Anderson LM, Kyrtopoulos SA. DNA adducts and liver DNA replication in rats during chronic exposure to N-nitrosodimethylamine (NDMA) and their relationships to the dose-dependence of NDMA hepatocarcinogenesis. *Mutat Res.* 2002;500:75-87. doi: 10.1016/s0027-5107(01)00301-3.
26. Chhabra SK, Anderson LM, Perella C, Desai D, Amin S, Kyrtopoulos SA, **Souliotis VL**. Coexposure to ethanol with N-nitrosodimethylamine or 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone during lactation of rats: marked increase in O(6)-methylguanine-DNA adducts in maternal mammary gland and in suckling lung and kidney. *Toxicol Appl Pharmacol.* 2000;169:191-200. doi: 10.1006/taap.2000.9068.
27. **Souliotis VL**, van Delft JH, Steenwinkel MJ, Baan RA, Kyrtopoulos SA. DNA adducts, mutant frequencies and mutation spectra in lambda lacZ transgenic mice treated with N-nitrosodimethylamine. *Carcinogenesis.* 1998;19:731-9. doi: 10.1093/carcin/19.5.731.
28. Sfrikakis PP, Dimopoulos MA, **Souliotis VL**, Charalambopoulos D, Mavrikakis M, Panayiotidis P. Effects of 2-chlorodeoxyadenosine and gold sodium thiomalate on human bcl-2 gene expression. *Immunopharmacol Immunotoxicol.* 1998;20:63-77. doi: 10.3109/08923979809034809.

29. Saunders MP, Salisbury AJ, O'Byrne KJ, **Souliotis VL**, Varcoe SM, Talbot DC, Kyrtopoulos SA, Harris AL. A phase II study evaluating the effect of tamoxifen on DNA repair in melanoma patients treated with dacarbazine. *Anticancer Res.* 1997;17:4677-80. PMID: 9494588
30. Kyrtopoulos SA, Anderson LM, Chhabra SK, **Souliotis VL**, Pletsa V, Valavanis C, Georgiadis P. DNA adducts and the mechanism of carcinogenesis and cytotoxicity of methylating agents of environmental and clinical significance. *Cancer Detect Prev.* 1997;21:391-405. PMID: 9307842.
31. Sfrikakis PP, **Souliotis VL**, Akbar AN, Katsilambros N, Hoffbrand VA, Panayiotidis P. Regulation of bcl-2 and fas expression in primary activation of human peripheral lymphocytes is not sensitive to dexamethasone or cyclosporin-A. *Hum Immunol.* 1996;50:121-6. doi: 10.1016/0198-8859(96)00136-x.
32. Kyrtopoulos SA, **Souliotis VL**, et al. DNA damage studies related to the assessment of the role of N-nitroso compounds in human cancer. *Eur J Cancer Prev.* 1996 Sep;5 Suppl 1:109-14. PMID: 8972304.
33. Farmer PB, Sepai O, Lawrence R, Autrup H, Sabro Nielsen P, Vestergård AB, Waters R, Leuratti C, Jones NJ, Stone J, Baan RA, van Delft JH, Steenwinkel MJ, Kyrtopoulos SA, **Souliotis VL**, et al. Biomonitoring human exposure to environmental carcinogenic chemicals. *Mutagenesis.* 1996;11:363-81. doi: 10.1093/mutage/11.4.363.
34. Chhabra SK, **Souliotis VL**, Kyrtopoulos SA, Anderson LM. Nitrosamines, alcohol, and gastrointestinal tract cancer: recent epidemiology and experimentation. *In Vivo.* 1996;10:265-84. PMID: 8797028.
35. **Souliotis VL**, Valavanis C, Boussiotis VA, Pangalis GA, Kyrtopoulos SA. Comparative study of the formation and repair of O6-methylguanine in humans and rodents treated with dacarbazine. *Carcinogenesis.* 1996;17:725-32. doi: 10.1093/carcin/17.4.725.
36. Sfrikakis PP, **Souliotis VL**, Katsilambros N, Markakis K, Vaiopoulos G, Tsokos GC, Panayiotidis P. Downregulation of interleukin-2 and alpha-chain interleukin-2 receptor biosynthesis by cisplatin in human peripheral lymphocytes. *Clin Immunol Immunopathol.* 1996;79:43-9. doi: 10.1006/clin.1996.0049.
37. Anderson LM, **Souliotis VL**, Chhabra SK, Moskal TJ, Harbaugh SD, Kyrtopoulos SA. N-nitrosodimethylamine-derived O(6)-methylguanine in DNA of monkey gastrointestinal and urogenital organs and enhancement by ethanol. *Int J Cancer.* 1996;66:130-4. doi: 10.1002/(SICI)1097-0215(19960328)66:1<130::AID-IJC22>3.0.CO;2-G.
38. Philip PA, **Souliotis VL**, Harris AL, Salisbury A, Tates AD, Mitchell K, van Delft JH, Ganesan TS, Kyrtopoulos SA. Methyl DNA adducts, DNA repair, and hypoxanthine-guanine phosphoribosyl transferase mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyurea. *Clin Cancer Res.* 1996;2:303-10. PMID: 9816173.
39. Bianchini F, Weiderpass E, Kyrtopoulos S, **Souliotis VL**, Henry-Amar M, Wild CP, Boffetta P. Detection of DNA methylation adducts in Hodgkin's disease patients treated with procarbazine. *Biomarkers.* 1996;1:226-31. doi: 10.3109/13547509609079362.
40. Van Delft JH, Luiten-Schuite A, **Souliotis VL**, Kyrtopoulos SA, Ouwerkerk J, Keizer HJ, Baan RA. N7-Methylguanine and O(6)-methylguanine levels in DNA of white blood cells

- from cancer patients treated with dacarbazine. *Biomarkers*. 1996;1:94-8. doi: 10.3109/13547509609088676.
41. Chhabra SK, **Souliotis VL**, Harbaugh JW, Krasnow SW, Jones AB, et al. O6-methylguanine DNA adduct formation and modulation by ethanol in placenta and fetal tissues after exposure of pregnant patas monkeys to N-nitrosodimethylamine. *Cancer Res*. 1995;55:6017-20. PMID: 8521384.
 42. **Souliotis VL**, Chhabra S, Anderson LM, Kyrtopoulos SA. Dosimetry of O6-methylguanine in rat DNA after low-dose, chronic exposure to N-nitrosodimethylamine (NDMA). Implications for the mechanism of NDMA hepatocarcinogenesis. *Carcinogenesis*. 1995;16:2381-7. doi: 10.1093/carcin/16.10.2381.
 43. Anderson LM, Chhabra SK, Nerurkar PV, **Souliotis VL**, Kyrtopoulos SA. Alcohol-related cancer risk: a toxicokinetic hypothesis. *Alcohol*. 1995;12:97-104. doi: 10.1016/0741-8329(94)00089-1.
 44. Pletsa V, Troungos C, **Souliotis VL**, Kyrtopoulos SA. Comparative study of mutagenesis by O6-methylguanine in the human Ha-ras oncogene in E. coli and in vitro. *Nucleic Acids Res*. 1994; 22:3846-53. doi: 10.1093/nar/22.19.3846.
 45. **Souliotis VL**, Valavanis C, Boussiotis VA, Pangalis GA, Kyrtopoulos SA. Comparative dosimetry of O6-methylguanine in humans and rodents treated with procarbazine. *Carcinogenesis*. 1994;15:1675-80. doi: 10.1093/carcin/15.8.1675.
 46. Valavanis C, **Souliotis VL**, Kyrtopoulos SA. Differential effects of procarbazine and methylnitrosourea on the accumulation of O6-methylguanine and the depletion and recovery of O6-alkylguanine-DNA alkyltransferase in rat tissues. *Carcinogenesis*. 1994;15:1681-8. doi: 10.1093/carcin/15.8.1681.
 47. Theocharis SE, **Souliotis VL**, Panayiotidis PG. Suppression of interleukin-1 beta and tumour necrosis factor-alpha biosynthesis by cadmium in in vitro activated human peripheral blood mononuclear cells. *Arch Toxicol*. 1994;69:132-6. doi: 10.1007/s002040050148
 48. Kyrtopoulos SA, **Souliotis VL**, Valavanis C, Boussiotis VA, Pangalis GA. Accumulation of O6-methylguanine in human DNA after therapeutic exposure to methylating agents and its relationship with biological effects. *Environ Health Perspect*. 1993;99:143-7. doi: 10.1289/ehp.9399143.
 49. Sfikakis PP, **Souliotis VL**, Panayiotidis PP. Suppression of interleukin-2 and interleukin-2 receptor biosynthesis by gold compounds in in vitro activated human peripheral blood mononuclear cells. *Arthritis Rheum*. 1993;36:208-12. doi: 10.1002/art.1780360211.
 50. **Souliotis VL**, Zongza V, Nikolopoulou V, Dimitriadis GJ. Measurement of O6-methylguanine-type adducts in DNA and O6-alkylguanine-DNA-alkyltransferase repair activity in normal and neoplastic human tissues. *Comp Biochem Physiol B*. 1992;101:269-75. doi: 10.1016/0305-0491(92)90189-x.
 51. **Souliotis VL**, Boussiotis VA, Pangalis GA, Kyrtopoulos SA. In vivo formation and repair of O6-methylguanine in human leukocyte DNA after intravenous exposure to dacarbazine. *Carcinogenesis*. 1991;12:285-8. doi: 10.1093/carcin/12.2.285.
 52. **Souliotis VL**, Patrino-Georgoula M, Zongza V, Dimitriadis GJ. The urea-soluble low molecular weight cuticle proteins from the different developmental stages of *Dacusoleae*. *Cell Differ Dev*. 1990;31:23-9. doi: 10.1016/0922-3371(90)90087-d.

53. **Souliotis VL**, Kaila S, Boussiotis VA, Pangalis GA, Kyrtopoulos SA. Accumulation of O6-methylguanine in human blood leukocyte DNA during exposure to procarbazine and its relationships with dose and repair. *Cancer Res.* 1990;50:2759-64. PMID: 2328502.
54. **Souliotis VL**, Kyrtopoulos SA. A novel, sensitive assay for O6-methyl- and O6-ethylguanine in DNA, based on repair by the enzyme O6-alkylguanine-DNA-alkyltransferase in competition with an oligonucleotide containing O6-methylguanine. *Cancer Res.* 1989;49:6997-7001. PMID: 2684406.
55. **Souliotis VL**, Giannopoulos A, Koufakis I, Kaila S, et al. Development and validation of a new assay for O6-alkylguanine-DNA-alkyltransferase based on the use of an oligonucleotide substrate, and its application to the measurement of DNA repair activity in extracts of biopsy samples of human urinary bladder mucosa. *Carcinogenesis.* 1989;10:1203-8. doi: 10.1093/carcin/10.7.1203.
56. **Souliotis VL**, Dimitriadis GJ. Identification and molecular analysis of the cuticle protein genes of *Dacusoleae*. *Insect Biochem.* 1989;19:499-507.
57. **Souliotis VL**, Patrino-Georgoula M, Zongza V, Dimitriadis GJ. Isolation and characterization of mRNAs coding for the third instar larvae cuticle proteins of *Dacus oleae*. *Insect Biochem.* 1988;18:829-37.
58. Patrino-Georgoula M, **Souliotis VL**, Dimitriadis GJ. A study on the developmental appearance of serum proteins and its mRNA in the insect *Dacus oleae*. *Comp Biochem Physiol B.* 1987;87:179-88.

SUPERVISION OF GRADUATE STUDENTS AND POSTDOCTORAL FELLOWS

- 2000-present**
- Postdoctoral fellows: **4**
 - Ph.D. theses: **8** (Athens Medical School, National and Kapodistrian Univ. of Athens)
 - M.Sc. theses: **2** (Athens Medical School, National and Kapodistrian Univ. of Athens)
 - Undergraduate theses: **8** (Department of Biology, National and Kapodistrian Univ. of Athens)

FELLOWSHIPS AND AWARDS

- 2013–2014 Fellowship, Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
- 2018 Second award "Sotiris Papastamatis" of the Annual Greek Medical Congress, Athens
- 2017 Best poster award of the 68th Congress of the Hellenic Society for Biochemistry and Molecular, Athens

2012	Second award "Sotiris Papastamatis" of the Annual Greek Medical Congress, Athens
2011	Young Investigator Award of the International Myeloma Workshop, Paris
1996	First award of the 14th Panhellenic Rheumatology Congress, Athens
1995	Second award of the 85th Annual Meeting of the American Association for Cancer Research, Toronto, Ontario
1992	Second award "Sotiris Papastamatis" of the Annual Greek Medical Congress

INVITED PRESENTATIONS IN CONFERENCES

- Modern Molecular Developments: New Medicines - New Treatments, Hellenic Society of Head and Neck Cancer, December 2019, Athens
- 2nd Panhellenic Cancer Research Congress "A. Simeonidis", March 2019, Thessaloniki
- European Society for Medical Oncology (ESMO), October 2018, Munich, Germany
- 44th Annual Greek Medical Congress, May 2018, Athens
- 13th Educational Seminar on Molecular Oncology & Target Therapy, March 2017, Ioannina
- American Association of Cancer Research (AACR) Annual Meeting, April 2014, San Diego
- 53rd Annual Meeting of the American-Society-of-Hematology (ASH), December 2011, San Diego
- International Myeloma Foundation (IMF) Workshop, May 2011, Paris
- 37th Annual Panhellenic Medical Conference. May 2011, Athens
- European Environmental Mutagen Society (EEMS) Annual Meeting, September 2010, Oslo, Norway
- 51st Annual Meeting of the American-Society-of-Hematology (ASH), December 2009, New Orleans
- 48th Annual Meeting of the American Society for Hematology (ASH), December 2006. Orlando
- 85th Annual Meeting of the American Association for Cancer Research, 1995, Toronto, Canada
- 18th Annual Panhellenic Medical Conference, 1992, Athens

HONOR

Newspaper "To Vima", #16500, 15 April 2017, page 6/26-7/27.

URL: <http://www.tovima.gr/science/article/?aid=873950>

LIST OF PUBLICATIONS IN REFEREED GREEK JOURNALS

- Aslani-Gkotszamanidou M, **Souliotis VL**, Dimopoulos MA, Terpos E. Inhibition of histone deacetylase 8: A new therapeutic target for multiple myeloma. Archives of Hellenic Medicine. 2020;37:87-97.
- **Souliotis VL**, Sfikakis P. The reduced DNA repair capacity in the pathogenesis of autoimmunity. Hellenic Rheumatology. 2013;24:208-211.

CHAPTERS IN COLLECTIVE VOLUMES

- **Souliotis VL**, Kyrtopoulos SA. Dose-response relationships and potential thresholds in the induction of mutagenesis and the influence of DNA repair and cell cycle progression, in Dietrich C, Oesch F, Oesch-Bartlomowicz B, Waiss C. (eds): Mechanisms of chemical carcinogenesis and their impact on dose-response relationships-the examples of dioxin and benzo(a) pyrene. ECNIS Reviews 2008, pp 31-42.
- Kyrtopoulos SA, **Souliotis VL**, Ambatzi P, Pangalis G, Bousiotou V, Haritopoulos G, Davaris G. Novel, sensitive assays for O-6-alkylguanine and its repair and their application to studies of the molecular epidemiology of this lesion in human populations, in O'Neill IK, Chen J, Bartsch H (eds): Relevance to human cancer of N-nitroso compounds, tobacco smoke and mycotoxins. IARC Sci Publ. 1991;(105):78-82.

COLLABORATIONS

- Prof. **Meletios A Dimopoulos**, Rector of the National and Kapodistrian University of Athens, "Alexandra" Hospital, Athens, Greece
- Prof. **Petros P. Sfikakis**, Dean of the School of Medicine, Joint Rheumatology Program & First Department of Propedeutic Internal Medicine, National and Kapodistrian University of Athens Medical School, "Laikon" Hospital, Athens, Greece
- Prof. **Konstantinos N. Syrigos**, Third Department of Medicine, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece
- Prof. **Evangelos Terpos**, Department of Clinical Therapeutics, National and Kapodistrian University of Athens Medical School, Athens, Greece
- Prof. **Nikhil C. Munshi**, Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
- Prof. **Amanda Psyrris**, Department of Medical Oncology, National Kapodistrian University of Athens Medical School, "Attikon" Hospital, Athens, Greece.
- Prof. **Vassilis Gorgoulis**, Molecular Carcinogenesis Group, Department of Histology and Embryology, National and Kapodistrian University of Athens Medical School, Greece
- Dr. **Masood Shamma**, Department of Medical Oncology, Harvard (Dana Farber), Cancer Institute, VA Boston Health Care System, Boston, MA, USA
- Dr. **Maria Fousteri**, Institute for Fundamental Biomedical Research, Biomedical Sciences Research Center "Alexander Fleming", Vari, Athens, Greece
- Dr. **Dimitris Stellas**, Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute Frederick, MD 21702-1201, USA.